Jeff Stevens Insider Selling for 32,500 Shares of Andeavor (ANDV); Last Week NovoCure Limited (NVCR) Analysts

Andeavor’s director Jeff Stevens made a sale of 32,500 shares of the ‘s company in sold via broker dated January 12, 2018. These shares were unloaded at an average price per share of $117.1, for a cumulative transaction value of $3,804,705. It seems he is very active lately as in the last month, he quietly unloaded additional 25,000 shares of the company, worth $2,780,943 USD. Obviously, the trade created confusion, as Mr. Jeff presently has in hand 1.48 million shares, accounting for 0.94% of the Company‚Äôs market cap.

Among 5 analysts covering NovoCure (NASDAQ:NVCR), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. NovoCure has $43 highest and $16 lowest target. $27.20’s average target is 25.35% above currents $21.7 stock price. NovoCure had 6 analyst reports since October 27, 2015 according to SRatingsIntel. The company was maintained on Friday, July 29 by Wedbush. The rating was initiated by Wedbush on Tuesday, October 27 with “Outperform”. The stock of NovoCure Limited (NASDAQ:NVCR) has “Market Outperform” rating given on Tuesday, October 27 by JMP Securities. The stock of NovoCure Limited (NASDAQ:NVCR) has “Hold” rating given on Wednesday, December 2 by Deutsche Bank. Barclays Capital initiated the stock with “Underweight” rating in Tuesday, January 19 report. The firm earned “Overweight” rating on Tuesday, October 27 by JP Morgan. See NovoCure Limited (NASDAQ:NVCR) latest ratings:

The stock decreased 2.03% or $0.45 during the last trading session, reaching $21.7. About 753,535 shares traded. NovoCure Limited (NASDAQ:NVCR) has declined 0.43% since January 13, 2017 and is downtrending. It has underperformed by 17.13% the S&P500.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors. The company has market cap of $1.94 billion. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It currently has negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.

Among 10 analysts covering Andeavor (NYSE:ANDV), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. Andeavor has $147 highest and $96.0 lowest target. $120.78’s average target is 1.39% above currents $119.13 stock price. Andeavor had 15 analyst reports since August 14, 2017 according to SRatingsIntel. The rating was maintained by Barclays Capital on Tuesday, November 14 with “Overweight”. UBS maintained Andeavor (NYSE:ANDV) rating on Wednesday, November 15. UBS has “Buy” rating and $123 target. RBC Capital Markets maintained Andeavor (NYSE:ANDV) on Wednesday, October 18 with “Hold” rating. The stock of Andeavor (NYSE:ANDV) earned “Hold” rating by RBC Capital Markets on Thursday, November 9. On Thursday, November 2 the stock rating was upgraded by Evercore to “Buy”. RBC Capital Markets maintained Andeavor (NYSE:ANDV) on Thursday, October 12 with “Hold” rating. The firm earned “Hold” rating on Thursday, September 28 by Scotia Capital. Cowen & Co maintained it with “Buy” rating and $120.0 target in Thursday, September 28 report. The stock of Andeavor (NYSE:ANDV) has “Hold” rating given on Monday, October 16 by Jefferies. The company was downgraded on Thursday, September 28 by Howard Weil.

The stock increased 1.45% or $1.7 during the last trading session, reaching $119.13. About 1.05 million shares traded. Andeavor (NYSE:ANDV) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Andeavor, through its subsidiaries, operates as an independent petroleum refining, logistics, and marketing firm in the United States. The company has market cap of $18.74 billion. The firm operates through three divisions: Refining, TLLP, and Marketing. It has a 21.59 P/E ratio. The Refining segment refines crude oil and other feed stocks into transportation fuels, such as gasoline and gasoline blend stocks, jet fuel, and diesel fuel, as well as other products, including heavy fuel oils, liquefied petroleum gas, petroleum coke, calcined coke, and asphalt.

Investors sentiment decreased to 0 in Q3 2017. Its down 1.62, from 1.62 in 2017Q2. It fall, as 410 investors sold Andeavor shares while 1 reduced holdings. 0 funds opened positions while 0 raised stakes. 76,384 shares or 99.94% less from 117.84 million shares in 2017Q2 were reported. Shell Asset accumulated 0.02% or 22,985 shares. Daiwa Sb Investments Ltd accumulated 1,210 shares. Gulf Bancorporation (Uk) reported 0.07% of its portfolio in Andeavor (NYSE:ANDV). Palisade Asset Mngmt Ltd Llc has 3,000 shares.